McDowell Caryn Gordon 4
4 · Revance Therapeutics, Inc. · Filed Jan 3, 2020
Insider Transaction Report
Form 4
McDowell Caryn Gordon
SVP, GC & Secretary
Transactions
- Other
Common Stock
2019-12-31$10.82/sh+382$4,133→ 24,317 total
Footnotes (1)
- [F1]These shares were acquired by Mrs. McDowell under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 31, 2019 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mrs. McDowell purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2019.